Expert Ratings for Legend Biotech
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 12 analysts have published their opinion on Legend Biotech (NASDAQ:LEGN) stock, with an average price target of $76.25, implying an upside from the current price of $63.64. The average price target has increased by 7.9% over the past month.
May 25, 2023 | 7:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech (NASDAQ:LEGN) has received positive ratings from 12 analysts over the past 3 months, with an average price target of $76.25, indicating an upside potential from the current price of $63.64.
The 12 analysts covering Legend Biotech have provided positive ratings, with an average price target of $76.25, which is higher than the current price of $63.64. This indicates that the stock has potential for growth in the short term. The average price target has also increased by 7.9% over the past month, showing a positive trend in analyst sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100